×
Organigram Holdings SG&A Expenses 2019-2024 | OGI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Organigram Holdings sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Organigram Holdings SG&A Expenses 2019-2024 | OGI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Organigram Holdings sg&a expenses from 2019 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$205.5B
Stryker (SYK)
$138.7B
Boston Scientific (BSX)
$121.5B
Medtronic (MDT)
$113.7B
EssilorLuxottica (ESLOY)
$104.2B
Haleon (HLN)
$48.6B
Lonza Group Ag (LZAGY)
$45.9B
ResMed (RMD)
$36.9B
Koninklijke Philips (PHG)
$29.3B
Terumo (TRUMY)
$27.8B
Zimmer Biomet Holdings (ZBH)
$21.6B
Baxter (BAX)
$20.3B
Insulet (PODD)
$16.5B
Smith & Nephew SNATS (SNN)
$13.5B
Bio-Rad Laboratories (BIO)
$9.3B
Demant (WILYY)
$9.2B
BellRing Brands (BRBR)
$7.7B
Lantheus Holdings (LNTH)
$7.3B
ICU Medical (ICUI)
$4.3B
Haemonetics (HAE)
$3.9B
TG Therapeutics (TGTX)
$3.9B
GN Store Nord (GNNDY)
$3.8B
Perrigo (PRGO)
$3.8B
Neogen (NEOG)
$3.7B
Prestige Consumer Healthcare (PBH)
$3.6B
Envista Holdings (NVST)
$3.3B
QuidelOrtho (QDEL)
$3.1B
Agios Pharmaceuticals (AGIO)
$2.6B
Maravai LifeSciences Holdings (MRVI)
$2.3B
Green Thumb Industries (GTBIF)
$2.2B